NCT05979948View on ClinicalTrials.gov

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

April 1, 2025

Study Completion Date

December 1, 2025

Conditions
Waldenström's Macroglobulinemia
Interventions
DRUG

Zanubrutinib

Zanubrutinib, 160 mg oral capsules twice daily for 12 months

DRUG

Bendamustine

Bendamustine, 70-90 mg/m2 on days 1 and 2 of each cycle for 6 cycles.

DRUG

Rituximab

Rituximab, 375 mg/m2 intravenously on day 0 of each cycle for 6 cycles

Trial Locations (1)

200020

RECRUITING

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
collaborator

RenJi Hospital

OTHER

collaborator

Huashan Hospital

OTHER

collaborator

Shanghai 6th People's Hospital

OTHER

collaborator

Huadong Hospital

OTHER

lead

Shanghai Changzheng Hospital

OTHER